Diabetic eye exam outreach: exam pages, retinal camera and AI screening claims, Medicare coverage, recall texts and closing the loop

Diabetic eye exam outreach asks a person who feels fine and sees fine to book an exam for an eye disease that may cause no symptoms at first. The federal sources are clear that a yearly dilated exam matters for people with diabetes, so the message itself is not in doubt. What goes wrong is the detail: promises that an exam prevents blindness, a retinal photo in a primary care office sold as a full eye exam, an AI screening result described as a diagnosis, coverage stated as free, or a recall text that tells a whole household the patient has diabetes. The program may be an optometry or ophthalmology practice that reminds its patients with diabetes, a primary care office or community health center with a retinal camera, an endocrinology practice that refers out, a pharmacy or a health fair. This guide covers how to word the exam page, how to describe retinal cameras and AI screening devices within what FDA has authorized, how to explain Medicare coverage, how to word recall texts, and how to close the loop between the office that screens and the eye doctor who follows up.

Eight related topics have their own guides and are not repeated here. Eye practices are covered in our guides to optometry marketing, retina practice marketing and glaucoma practice marketing. Diabetes programs are covered in our guides to diabetes education program marketing and endocrinology practice marketing. Primary care offices are covered in our guides to primary care practice marketing and annual wellness visit outreach, and screening events in our guide to health fair and screening event marketing. For exam offers that involve glasses or contacts, see our guide to the Contact Lens Rule and Eyeglass Rule for eye care ads and offers.

What the federal sources say

The National Eye Institute (NEI), the CDC, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), MedlinePlus from the National Library of Medicine and Medicare.gov publish the federal positions on eye exams for people with diabetes. The points that shape an outreach program’s marketing:

• The NEI page Diabetic Retinopathy (last updated September 11, 2025) says people with diabetes should get a comprehensive dilated eye exam at least once a year, that diabetic retinopathy may not have any symptoms at first, that anyone with any kind of diabetes can get it, including type 1, type 2 and gestational diabetes, and that the risk increases the longer a person has diabetes. It says treatment will not undo damage to vision but can stop vision from getting worse.
• The CDC page Vision Loss and Diabetes (updated May 15, 2024, read through an archived copy) tells people with diabetes to get a dilated eye exam at least once a year, says a person diagnosed with type 2 diabetes should have an eye exam for diabetic retinopathy right away and a person with type 1 diabetes within 5 years of diagnosis, and describes cataracts and glaucoma as other eye diseases linked to diabetes.
• The NEI page Get a Dilated Eye Exam (last updated November 26, 2025) says vision may be blurry and the eyes sensitive to light for a few hours after the exam, and tells people to ask a friend or family member to drive them home.
• The MedlinePlus page Diabetic Eye Problems (last updated November 13, 2024) explains the eye problems diabetes can cause in plain words and can be linked from a practice page as reading before the visit.
• The Medicare.gov page Eye exams (for diabetes), checked on October 30, 2026, says Part B covers eye exams for diabetic retinopathy once a year for people with diabetes, from an eye doctor who is legally allowed to do the test in the state, and that the person pays 20 percent of the Medicare-approved amount for the doctor’s services after the Part B deductible, with a copayment in a hospital outpatient setting.

The federal pages differ on one group. The NEI page says women with diabetes who become pregnant, and women who develop gestational diabetes, are at high risk for diabetic retinopathy. The NIDDK page Diabetic Eye Disease was last reviewed in May 2017, and it says gestational diabetes does not generally cause eye problems. On a page about pregnancy, quote the newer NEI page with its date and say the patient’s own clinicians set the timing of exams in pregnancy.

We also checked the treatment wording against FDA’s records, because older pages can trail newer approvals. The NEI page, updated in 2025, already describes injections, laser treatment and surgery as treatments, so the page has no “no treatment” wording to correct. Describe treatment in NEI’s words, name no drug or device, and leave the choice of treatment to the eye doctor.

Two points shape the marketing. First, the message is a yearly dilated exam, not a promise: NEI says treatment can stop vision from getting worse, not that an exam prevents vision loss. Second, coverage and recommendation are separate. Medicare covers a yearly eye exam for diabetic retinopathy, and Medicare.gov says it does not cover routine eye exams for glasses or contact lenses; a page that reads “Medicare covers your eye exam” without saying which exam mixes the two.

Exam pages and claims that need rewriting

Google’s search suggestions, which we checked on October 30, 2026, offer “diabetic eye exam near me”, “diabetic eye exam cost”, “diabetic eye exam cost without insurance”, “diabetic eye exam in spanish” and “diabetic eye exam report” to a person who types “diabetic eye exam”, “diabetic retinopathy screening test”, “diabetic retinopathy screening camera” and “diabetic retinopathy screening cost” after “diabetic retinopathy screening”, “diabetic eye exam covered by medicare” and “does medicare cover diabetic eye exam” after “diabetic eye exam medicare”, and “retinal imaging vs dilation” and “retinal imaging worth it” after “retinal imaging”. A page can answer each of those honestly: what the exam involves, how a retinal photo differs from a dilated exam, what the exam costs and who pays, which language the practice offers, and what report the eye doctor sends back to the patient’s diabetes care team.

A page that holds up says who the exam is for, that diabetic retinopathy may have no symptoms at first, that the federal sources advise a dilated eye exam at least once a year, and what happens at the visit, including drops that widen the pupil and blurry vision for a few hours after. It tells the patient to bring sunglasses and arrange a ride, names the eye doctor and their license, says how results are shared with the patient’s primary care or diabetes clinician, and links the NEI or MedlinePlus pages. The page also has to work for readers with low vision: large text that resizes, strong contrast and buttons that work with a screen reader, as our guide to website accessibility for medical practices explains.

Phrases that need rewriting:

• “A yearly exam prevents blindness.” NEI says treatment will not undo damage but can stop vision from getting worse. Say a yearly dilated exam helps find eye problems early, in the words of a named and dated source, and promise no outcome.
• “No symptoms means your eyes are healthy.” NEI says diabetic retinopathy may not have any symptoms at first. Say that is why the exam matters even when vision seems fine.
• “Our retinal photo replaces your dilated eye exam.” A retinal photo or an AI screening result is a screening step. Say what the office does, who reads the images, and that a patient with a positive or unreadable result is referred to an eye doctor.
• “FDA-approved AI diagnoses diabetic eye disease.” The device type was granted through the De Novo pathway and later devices were cleared through 510(k), and the federal rule for the device type calls its output a screening diagnosis only. Say “FDA-authorized” or “FDA-cleared” only as the device’s own record states, name no brand, and say an eye doctor confirms and treats.
• “Free diabetic eye exam with Medicare.” Medicare.gov says the patient pays 20 percent of the Medicare-approved amount after the Part B deductible. Describe the cost as Medicare.gov states it, and say the practice checks coverage for each patient.
• “Eye vitamins protect your eyes from diabetes.” A supplement claim with no source. Remove it, and follow the supplement section below.
• “We’ve saved hundreds of patients’ sight.” Outcome numbers with no source. Remove them unless they are drawn from the practice’s own documented and reviewed records, with their date and limits stated.

Under 15 U.S.C. 45, deceptive acts or practices in commerce are unlawful, and 15 U.S.C. 52 prohibits false advertisements likely to induce the purchase of drugs, devices, services or cosmetics. The FTC staff Health Products Compliance Guidance says claims about the health benefits or safety of health-related products require competent and reliable scientific evidence, and that an advertiser is responsible for the claims its ads convey, including implied ones. Quoting the federal sources as written, with each one named and dated, stays inside that standard; turning a federal statement into a promise to the reader does not.

Symptoms, urgent signs and 911 on every page and in every tool

A yearly exam is for people whose eyes seem fine, so the page has to send people with new symptoms elsewhere. The NEI page says that in later stages a person may see dark, floating spots or streaks, and that it is important to get treatment right away even if the spots clear up. The NIDDK page, last reviewed in May 2017, tells people to call a doctor right away for sudden changes in vision, including flashes of light or a sudden rise in floaters, or if it looks like a curtain is pulled over the eyes, and says these can be signs of a detached retina, which is a medical emergency. Put plain lines above the booking button and on flyers: if your vision changes suddenly, or you see new spots, flashes or a shadow like a curtain, call [phone] now; do not wait for a yearly exam. Call 911 for an emergency.

The same wording belongs in voicemail, after-hours greetings, portal replies, text replies, chat and AI front desk tools, and on cards handed out at a screening event. A tool should hand any message about a change in vision to a clinician or the on-call line, send any message about an emergency to the 911 line and alert staff, pass questions about results to a clinician, and never explain a retinal photo or a screening result itself. Our guides to the AI chatbot on a practice website and answering service versus AI receptionist cover how tools hand off these messages.

Retinal cameras and AI screening in a primary care office

Primary care offices, endocrinology practices and community health centers can take retinal photos during a diabetes visit, read by an eye doctor at a distance or by an AI screening device. Search suggestions such as “diabetic retinopathy screening camera” and “retinal imaging vs dilation” show that patients ask how this differs from a dilated exam, and the marketing has to answer within what FDA has authorized.

FDA’s De Novo database shows that FDA granted a De Novo request for a diabetic retinopathy detection device on April 11, 2018. That created the device type in 21 CFR 886.1100, a retinal diagnostic software device, which the rule defines as a prescription software device that uses an adaptive algorithm to evaluate eye images for diagnostic screening, in class II with special controls. Our check of the FDA 510(k) database on October 30, 2026 found seven later clearances under the same product code, the latest on July 2, 2026. The rule requires each device’s labeling to warn that the device is not to be used to screen for diseases or conditions beyond its indicated uses, that it provides a screening diagnosis only and that it is critical the patient be advised to receive follow-up care, and that it does not treat the screened disease.

Keep these points:

• Describe the device by what its own FDA record and labeling say it does, for whom and with which camera, confirmed with the maker, and name no brand. Say “authorized” for a De Novo device and “cleared” for a 510(k) device; do not call either one “approved”.
• Say the result is a screening result, not a full eye exam, and that a patient with a positive result, or an image that cannot be read, is referred to an eye doctor for a dilated exam.
• Do not claim the device finds glaucoma, cataracts or other eye diseases unless its labeling covers them; the rule warns against use beyond the indicated uses.
• Do not quote the device’s accuracy figures unless they come from its FDA summary or labeling, with the source and date, and with the population it was tested in.
• Say who in the office takes the photos and that they are trained, since the rule requires the maker to provide a training program for taking quality images.

Closing the loop between the screening office and the eye doctor

Outreach fails quietly when a patient is screened or referred and nobody checks that the exam happened. The search suggestion “diabetic eye exam report” points to the other half of the job: the eye doctor’s findings going back to the clinician who manages the diabetes. A page for primary care or endocrinology can say which eye doctors the practice refers to, that the patient may choose another, and that the practice asks for the exam report. A page for an eye practice can say it sends a report to the patient’s diabetes clinician with the patient’s agreement, and how fast.

Referral relationships follow our guide to patient and physician referrals. Do not tell patients they must use one eye practice, and do not pay or accept anything of value for referrals, as the section on partners below explains.

Supplements and eye vitamins

Supplements offered for eye health in diabetes need the same care as any health claim. The FDA Questions and Answers on Dietary Supplements (content current as of August 27, 2026) says FDA does not have the authority to approve dietary supplements before they are marketed. Name no product, make no claim that a supplement prevents, slows or treats diabetic eye disease, and follow our guide to selling supplements in a medical practice.

Recall texts, letters and reminders

Outreach programs reach patients through recall lists: patients with diabetes with no eye exam on file in the past year, patients newly diagnosed with type 2 diabetes, and patients with a positive screening result who have not seen an eye doctor. Under 45 CFR 164.501, a communication about the practice’s own treatment for an individual, such as a reminder to come in for a recommended exam, can fall outside the definition of marketing, while a message that promotes a third party’s product or service generally needs a signed authorization under 45 CFR 164.508.

The words in the message matter as much as the rule. A text, a postcard or a voicemail can be seen by a partner, a family member or an employer. Keep these points:

• Name no condition, no result and no test in the message text. Write “[Practice name]: it is time for your yearly eye exam. Call [phone] or book online.” and give details only after the patient signs in or calls.
• Do not write “diabetic eye exam” or “diabetes” on a postcard, an envelope, a caller ID name or a voicemail.
• A follow-up reminder after a positive screening can say “Please call [phone] to schedule your follow-up visit.” without naming the result.
• Add a line to each reminder for the visit itself: plan a ride home and bring sunglasses, since NEI says vision may be blurry for a few hours after dilation.
• Send messages in the language the patient chose, use the contact method the patient chose, and honor opt-out requests in every channel.
• Do not send recall lists or screening results to an ad platform to build an audience.

Our guides to text message appointment reminders and the patient recall system cover consent, timing and opt-outs.

Coverage, costs and free exams

Coverage pages draw the “diabetic eye exam cost” and “does medicare cover diabetic eye exam” searches. Medicare.gov says Part B covers an eye exam for diabetic retinopathy once a year for people with diabetes, and that the person pays 20 percent of the Medicare-approved amount for the doctor’s services after the Part B deductible, plus a copayment in a hospital outpatient setting. Its Glaucoma screenings page lists diabetes among the conditions that make a person eligible for a glaucoma screening once every 12 months, with the same 20 percent after the deductible. Its Eye exams (routine) page says Medicare does not cover routine eye exams for glasses or contact lenses. Describe each in those terms, keep the exam for diabetic retinopathy separate from an exam for glasses, and say the practice checks coverage for each patient. Medicare messaging follows our guide to marketing to Medicare patients.

Private plans are a separate question. Under 42 U.S.C. 300gg-13, group health plans and health insurers must cover, without cost sharing, evidence-based items or services that have a rating of “A” or “B” in the current USPSTF recommendations, along with other listed preventive services. Do not write “free under the ACA” or “covered by all insurance” for an eye exam unless the plan confirms it; say the practice checks coverage before the visit. Cash prices for an eye exam or a retinal photo follow our guides to advertising cash prices and good faith estimates for self-pay patients.

A “free” eye exam, a free retinal photo at a health fair or a gift card for coming in follows 16 CFR 251.1, which says a free offer must not be recouped through a raised price or a reduced quantity or quality elsewhere, and that the terms of the offer should be stated at the outset. Under 42 U.S.C. 1320a-7a(a)(5), civil penalties can apply to a person who offers or transfers remuneration to a Medicare or state health care program beneficiary that the person knows or should know is likely to influence the beneficiary to order or receive items or services from a particular provider, practitioner or supplier. Free exams and incentives need counsel’s review before they run. At a health fair, do not take retinal photos without a plan for who reads them, who calls each person and who arranges an eye doctor visit after a positive or unreadable result, including for people with no regular eye doctor.

Partners, sponsors and referral payments

Under 42 U.S.C. 1320a-7b(b), the federal anti-kickback statute, it is a crime to knowingly and willfully offer, pay, solicit or receive any remuneration to induce or reward referrals of items or services payable by a federal health care program. Rules on referral fees are also set state by state.

For a diabetic eye exam program, keep these points:

• Do not accept a free camera, free reading services, staff or marketing help from an eye practice, a reading service or a device maker tied to the referrals that follow, without counsel’s review; our guide to Open Payments covers reported payments from manufacturers.
• Do not steer patients with a positive result to one eye practice in exchange for anything of value, and do not pay a primary care office, a pharmacy or an outreach worker per patient sent for an exam without counsel’s review.
• If an eye practice and a primary care office share a camera, a space or staff, put the terms in writing and have counsel review them before any marketing mentions the arrangement.

Privacy, pixels and ads

A visit to a diabetic eye exam page, a screening result question or a booking form says the person has diabetes. Keep form answers, bookings and page clicks out of tracking pixels and ad platform tools unless a written agreement covers them; our guide to tracking pixels on practice websites covers the setup. The Google Ads personalized advertising policy lists health among its sensitive interest categories and restricts targeting based on it. Ads can target by place, language settings and search terms, and should not be built from a list of patients with diabetes.

Tone and patient stories

People with diabetes hear a long list of tests and warnings, and fear of losing sight can make some put the exam off rather than book it. Lead with what the exam is and how simple the visit can be, say there may be no symptoms at first, offer evening or weekend times if the practice has them, and keep fear out of it: no images of blindness, no countdowns, no wording that blames the patient for their blood sugar. Use person-first words such as “people with diabetes”, and offer the page in the languages the practice’s patients speak; our guide to Spanish language medical marketing covers translation.

A story from a patient who came in for a yearly exam can carry the message. Under 16 CFR 255.2, an ad that shows one person’s result on a key attribute is likely to be read as what others will generally achieve, unless the advertiser has substantiation for that or clearly and conspicuously discloses what people can generally expect. A story of sight saved by an exam is that kind of claim. Pair the story with the attributed federal statement, say results differ, and get a signed authorization under 45 CFR 164.508 where the practice is a covered entity. A story should not name a diagnosis, a treatment or a result unless the patient chose to share it in writing; say if the person received anything for taking part, and let them review the final version. Our guides to patient photo consent and testimonials and before and after photos cover the full rules.

Illustration: two diabetic eye exam outreach messages

Illustration: a flyer reads “Diabetic? Don’t go blind! Our FDA-approved AI camera diagnoses eye disease in minutes, no need to see an eye doctor. Free with Medicare. No symptoms? Your eyes are fine, but come in anyway for a free gift.” It uses fear, misnames the device’s FDA status and calls a screening result a diagnosis, drops the eye doctor follow-up, states coverage as free, tells readers with no symptoms their eyes are fine, and offers a gift without counsel’s review.

Illustration: a second flyer for the same practice reads “Have diabetes? Federal eye health sources advise a dilated eye exam at least once a year, because eye disease from diabetes may have no symptoms at first. At [Practice name], [Clinician name, license] does the exam and sends a report to your diabetes care team if you agree. Plan a ride home and bring sunglasses. Medicare Part B covers a yearly exam for diabetic eye disease; we check your coverage before the visit. Sudden change in vision, new spots or flashes, or a shadow like a curtain? Call [phone] now. Call 911 for an emergency. Call [phone] during [days and hours] to book.” It names the federal advice, describes coverage without a promise, keeps the result with the clinicians, and puts the urgent and emergency lines in plain view.

Checklist before a diabetic eye exam campaign goes live

• Exam copy built on the NEI and CDC pages, named and dated, with the yearly dilated exam, the timing after diagnosis for type 1 and type 2 diabetes, and no promise that an exam prevents vision loss.
• The page explains dilation, blurry vision for a few hours after, a ride home and sunglasses; NEI or MedlinePlus pages linked; text, contrast and buttons usable by readers with low vision.
• Pregnancy wording quotes the newer NEI page with its date and leaves exam timing to the patient’s clinicians.
• Retinal cameras and AI screening described by each device’s own FDA record and labeling, as authorized or cleared, never approved; a screening result, not a full exam; follow-up with an eye doctor for positive or unreadable results; no brand names and no accuracy figures without source and date.
• The urgent sign line and the 911 line on pages, flyers, event cards, voicemail, after-hours greetings, portal replies, text replies, chat and AI front desk tools, reviewed by the practice’s clinicians.
• Recall texts, postcards, caller ID names and voicemails name no condition, test or result; opt-outs honored; no recall lists sent to ad platforms.
• Medicare coverage described as Medicare.gov states it, with the exam for diabetic retinopathy kept separate from routine exams for glasses; private plan coverage checked per patient.
• Free exams, free photos at events and gift cards reviewed by counsel under 16 CFR 251.1 and 42 U.S.C. 1320a-7a(a)(5); every photo taken at an event has a reading, results and follow-up plan.
• No free cameras, reading services, staff or funding from eye practices, reading services or device makers tied to referrals, and no per-patient payments, without counsel’s review; the exam report goes back to the diabetes clinician with the patient’s agreement.
• No supplement claims; form answers, bookings and patient lists stay out of pixels and ad audiences; stories have signed authorizations and say results differ.

How we help

We build websites, local search, Google Ads and AI front desk tools for independent practices and health businesses, including optometry, ophthalmology, primary care, endocrinology and community health practices. For a diabetic eye exam program, that means a site that builds its exam page on the NEI and CDC guidance as written and dated, describes retinal cameras and AI screening within what FDA has authorized, explains Medicare coverage without a promise, puts the urgent sign and 911 lines above the booking button, works for readers with low vision, and answers “diabetic eye exam near me” and “does medicare cover diabetic eye exam” searches honestly, plus appointment request pages that book the exam and keep answers off the web and away from tracking tools. Our front desk tools hand changes in vision to a clinician or the on-call line, emergencies to the 911 line, and questions about results to a clinician, and do not explain screening results. We do not decide who should be screened or how; your clinicians and patients do. Our tools are built with HIPAA in mind. We confirm in writing what a BAA covers before any patient information flows through a tool, and if it is not covered, we do not route patient information through it. We are not a healthcare provider and we do not give legal or medical advice. We do not sell lead lists and we do not pay for referrals. For the wider rules, see our healthcare marketing rules hub.

Sources

• National Eye Institute: Diabetic Retinopathy (last updated September 11, 2025)
• National Eye Institute: Get a Dilated Eye Exam (last updated November 26, 2025)
• CDC: Vision Loss and Diabetes (updated May 15, 2024)
• NIDDK: Diabetic Eye Disease (last reviewed May 2017)
• MedlinePlus: Diabetic Eye Problems (last updated November 13, 2024)
• Medicare.gov: Eye exams (for diabetes) (checked October 30, 2026)
• Medicare.gov: Glaucoma screenings (checked October 30, 2026)
• Medicare.gov: Eye exams (routine) (checked October 30, 2026)
• 21 CFR 886.1100: Retinal diagnostic software device
• FDA: De Novo database, DEN180001 (decision April 11, 2018; checked October 30, 2026)
• FDA: 510(k) Premarket Notification database (checked October 30, 2026)
• FDA: Product Classification, product code PIB (checked October 30, 2026)
• 42 U.S.C. 300gg-13: Coverage of preventive health services
• 45 CFR 164.501: Definitions
• 45 CFR 164.508: Uses and disclosures for which an authorization is required
• 15 U.S.C. 45: Unfair methods of competition unlawful
• 15 U.S.C. 52: Dissemination of false advertisements
• FTC: Health Products Compliance Guidance (December 2022)
• FDA: Questions and Answers on Dietary Supplements (content current as of August 27, 2026)
• 16 CFR 251.1: Guide concerning use of the word free and similar representations
• 42 U.S.C. 1320a-7a: Civil monetary penalties
• 42 U.S.C. 1320a-7b: Criminal penalties for acts involving Federal health care programs
• 16 CFR 255.2: Consumer endorsements
• Google Ads: Personalized advertising policy

More in Physician specialty marketing